Physician profile
Peter Rosandich
NPI 1356435747
$2,297.61
in general payments reported to CMS, 2019-2025
16 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $218 · 2021: $184 · 2022: $593 · 2023: $525 · 2024: $144 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,037.24 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Janssen Scientific Affairs, LLC | $221.26 | 2022 | |
| Abbvie INC. | $195.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $141.03 | 2021 | |
| Horizon Therapeutics Plc | $129.61 | 2022-2023 | Tepezza |
| Radius Health, INC. | $121.80 | 2020 | |
| Janssen Biotech, INC. | $116.36 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $97.41 | 2022 | |
| Lilly USA, LLC | $59.02 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $55.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.38 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.38 | 2020 | |
| Biogen, INC. | $20.80 | 2021 | |
| Pfizer INC. | $15.68 | 2022 | |
| Lundbeck LLC | $14.37 | 2025 | Vyepti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $12.79 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rosandich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.